The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
YKL-40, a secreted glycoprotein, promotes tumor angiogenesis
Open accessAbstract
Tumor angiogenesis is of paramount importance in solid tumor development. Elevated serum levels of YKL-40, which is a secreted heparin-binding glycoprotein, have been associated with a worse prognosis from various advanced human cancers. Yet the role of YKL-40 activity in these cancers is still missing. In this study, we showed that ectopic expression of YKL-40 in MDA-MB-231 breast cancer cells and in HCT-116 colon cancer cells led to larger tumor formation with an extensive angiogenic phenotype than did control cancer cells in mice. Affinity-purified recombinant YKL-40 protein promoted vascular endothelial cell angiogenesis in vitro, the effects of which are similar to the activities observed using MDA-MB-231 and HCT-116 cell-conditioned medium after transfection with YKL-40. Furthermore, YKL-40 was found to induce coordination of membrane-bound receptor syndecan-1 and integrin αvβ3 and to activate an intracellular signaling cascade, including focal adhesion kinase and mitogen-activated protein kinase extracellular signal-related kinase1/2 in endothelial cells. Moreover, blockade of YKL-40 using small-interfering RNA gene knockdown suppressed tumor angiogenesis in vitro and in vivo. Immunohistochemical analysis of human breast cancer showed a correlation between YKL-40 expression and blood vessel density. These findings provide novel insights into angiogenic activities and molecular mechanisms of YKL-40 in cancer development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 2×
“A number of angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor have been shown to have critical roles in the development of tumor vasculature (Kim et al., 1993; Yancopoulos et al., 2000; Fahmy et al., 2003).”
BackgroundKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Functions of Cell Surface Heparan Sulfate Proteoglycans
Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., & Zako, M. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.729 · Cited by 2,688
A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF
Higashiyama, S., Abraham, J. A., Miller, J., Fiddes, J. C., & Klagsbrun, M. (1991) · Science · doi:10.1126/science.1840698 · Cited by 1,127 · cited 14×
“The lower chamber of transwells included YKL-40 (100 ng/ml), ySP (100 ng/ml) or VEGF (10 ng/ml).”
BackgroundInfluentialHakala, B. E., White, C., & Recklies, A. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74461-5 · Cited by 646
A public database for gene expression in human cancers.
Lal, A., Lash, A., Altschul, S. F., Velculescu, V. E., Zhang, L., McLendon, R. E., Marra, M. A., Prange, C. K., Morin, P. J., Polyák, K., et al. (1999) · PubMed · Cited by 414
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
Millauer, B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A., & Strawn, L. M. (1996) · PubMed · Cited by 413
Renkema, G. H., Boot, R. G., Au, F. L., Donker‐Koopman, W. E., Strijland, A., Muijsers, A. O., Hrebicek, M., & Aerts, J. M. F. G. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2510504.x · Cited by 402
Cited by
Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., Zhang, Z., Yang, S., & Xiao, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01744-8 · Cited by 977
Role of Chitin and Chitinase/Chitinase-Like Proteins in Inflammation, Tissue Remodeling, and Injury
Lee, C. G., Da Silva, C. A., Dela Cruz, C. S., Ahangari, F., Ma, B., Kang, M.-J., He, C.-H., Takyar, S., & Elias, J. A. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142250 · Cited by 896
Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis
Riabov, V., Gudima, A., Wang, N., Mickley, A., Orekhov, A., & Kzhyshkowska, J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00075 · Cited by 628
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., et al. (2021) · Brain · doi:10.1093/brain/awab223 · Cited by 598
Chitinase-3 like-protein-1 function and its role in diseases
Zhao, T., Su, Z., Li, Y., Zhang, X., & You, Q. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00303-7 · Cited by 536
Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor α2
He, C. H., Lee, C. G., Dela Cruz, C. S., Lee, C.-M., Zhou, Y., Ahangari, F., Ma, B., Herzog, E. L., Rosenberg, S. A., Li, Y., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.032 · Cited by 326
Cohen, N., Shani, O., Raz, Y., Sharon, Y., Hoffman, D., Abramovitz, L., & Erez, N. (2017) · Oncogene · doi:10.1038/onc.2017.65 · Cited by 292
In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases
Bonneh-Barkay, D., Wang, G., Starkey, A., Hamilton, R. L., & Wiley, C. A. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-34 · Cited by 291
YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
Llorens, F., Thüne, K., Tahir, W., Kanata, E., Diaz-Lucena, D., Xanthopoulos, K., Kovatsi, E., Pleschka, C., Garcia-Esparcia, P., Schmitz, M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0226-4 · Cited by 249
Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma
Francescone, R. A., Scully, S., Faibish, M., Taylor, S. L., Oh, D., Moral, L., Yan, W., Bentley, B., & Shao, R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.212514 · Cited by 261
Self-citationChitinases and chitinase-like proteins as biomarkers in neurologic disorders
Pinteac, R., Montalban, X., & Comabella, M. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000921 · Cited by 87
“Moreover, CHI3L1 is a potent angiogenic factor that promotes tumor angiogenesis.(47) Despite the apparent pathophysiologic implication of CHI3L1 in both inflammatory and reparative responses, there are many unknowns.”
BackgroundKoch, B. E., Stougaard, J., & Spaink, H. P. (2015) · Glycobiology · doi:10.1093/glycob/cwv005 · Cited by 72
Glycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications
Qusairy, Z., & Rada, M. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05303-1 · Cited by 16
Serum YKL-40 levels as a novel marker of inflammation in patients with endometriosis
Ural, Ü. M., Tekin, Y. B., Cüre, M. C., & Şahin, F. K. Ş. (2015) · Clinical and Experimental Obstetrics & Gynecology · doi:10.12891/ceog1882.2015 · Cited by 12
Metadata
- Authors
- Shao, R., Hamel, K., Petersen, L., Cao, Q. J., Arenas, R. B., Bigelow, C., Bentley, B., & Yan, W.
- Venue
- Oncogene
- Published
- 2009-09-21
- Volume
- 28
- Issue
- 50
- Pages
- 4456-4468
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2027072680
- Cited by
- 292
- References
- 40
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.